845 Results

People

  1. De Angelis
    De Angelis
  2. Dunkel
    Dunkel
  3. Mellinghoff
    Mellinghoff
  4. Karajannis
    Karajannis
  5. Abrey
    Abrey
  6. Omuro
    Omuro
  7. Souweidane
    Souweidane
  8. Rosenblum
    Rosenblum
  9. Pentsova
    Pentsova
  10. Khakoo
    Khakoo

Groups

  1. Tow Center for Developmental Oncology (TCDO) (239)
  2. Pediatrics, Department of (235)
  3. GSK Faculty (230)
  4. Neuro-Oncology Service (176)
  5. Survivorship Research (149)
  6. Human Oncology and Pathogenesis Program (129)
  7. Radiology, Department of (122)
  8. Neuroradiology Service (97)
  9. Department of Medicine (96)
  10. Department of Pathology and Laboratory Medicine (94)
  1. "Neuro-Oncology"
Formats
  1. Meeting Abstract (667)
  2. Journal Article (146)
  3. Review (14)
  4. Editorial (11)
  5. Guidelines (5)
  6. Correspondence (1)
  7. Research Letter (1)
Groups
  1. Tow Center for Developmental Oncology (TCDO) (239)
  2. Pediatrics, Department of (235)
  3. GSK Faculty (230)
  4. Neuro-Oncology Service (176)
  5. Survivorship Research (149)
  6. Human Oncology and Pathogenesis Program (129)

More Groups

People
  1. Lisa De Angelis (109)
  2. Ingo Mellinghoff (84)
  3. Ira Dunkel (84)
  4. Matthias Karajannis (66)
  5. Antonio Omuro (63)
  6. Lauren Abrey (63)

More People

Years
  1. 2025 (3)
  2. 2024 (67)
  3. 2023 (53)
  4. 2022 (62)
  5. 2021 (35)
  6. 2020 (66)

More Years

Publications
  1. Neuro-Oncology (845)
Publishers
  1. Oxford University Press (845)

Results (845)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Designing a time-dependent therapeutic strategy using CDK4/6 inhibitors in an intracranial ATRT model
    Journal Article

    Martin, B.; Guadix, S. W.; Sathian, R.; Laramee, M.; Pandey, A.; Ray, I.; Wang, A.; Davuluri, R.; Thomas, C. J.; Dahmane, N.; more...
    Neuro-Oncology (2025)

    Fulltext@MSK | Save
  • Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: A Children’s Oncology Group study
    Journal Article

    Karajannis, M. A.; Onar-Thomas, A.; Lin, T.; Baxter, P. A.; Boué, D. R.; Cole, B. L.; Fuller, C.; Haque, S.; Jabado, N.; Lucas, J. T. Jr; more...
    Neuro-Oncology (2025)

    Fulltext@MSK | Save
  • NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases
    Journal Article

    Le Rhun, E.; Nayak, L.; Lim-Fat, M. J.; Rudà, R.; Pentsova, E.; Forsyth, P.; O'Brien, B. J.; Preusser, M.; Kumthekar, P.; Brandsma, D.; more...
    Neuro-Oncology (2025)

    Fulltext@MSK | Save
  • Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma
    Journal Article

    Gallitto, M.; Zhang, X.; De Los Santos, G.; Wei, H. J.; Fernández, E. C.; Duan, S. F.; Sedor, G.; Yoh, N.; Kokossis, D.; Angel, J. C.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Evaluation of paxalisib in GBM AGILE phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Mellinghoff, I. K.; Cloughesy, T.; Alexander, B.; Berry, D. A.; Buxton, M.; Cavenee, W.; Colman, H.; de Groot, J.; Ellingson, B. M.; Gordon, G. B.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): Updated efficacy results
    Meeting Abstract

    Mellinghoff, I. K.; van den Bent, M. J.; Touat, M.; Blumenthal, D. T.; Peters, K. B.; Ellingson, B. M.; Clarke, J. L.; Mendez, J.; Yust-Katz, S.; Mason, W. P.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with TRK fusion primary central nervous system (CNS) tumors: An updated analysis
    Meeting Abstract

    Perreault, S.; Spano, J. P.; Nilsson, A.; Deyell, R. J.; Doz, F.; Geoerger, B.; Gumus, M.; Lassen, U. N.; Nysom, K.; Valero-Arrese, L.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, safety lead-in and randomized, open-label, perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH1 mutant glioma: Trial in progress
    Meeting Abstract

    Wen, P. T.; de la Fuente, M.; Kumthekar, P.; Peters, K.; Clarke, J.; de Groot, J.; Arrillaga-Romany, I.; Puduvalli, V.; Mellinghoff, I.; Chong, R.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy of AZD1390 + radiation therapy for glioblastoma
    Meeting Abstract

    Wen, P.; Yang, J. T.; Imber, B. S.; Drappatz, J.; Jena, R.; Forst, D.; Zukas, A.; Short, S. C.; Fan, C.; Trigg, W.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Outcome of patients with recurrent medulloblastoma and ependymoma treated with pembrolizumab, an immune checkpoint inhibitor: A Pediatric Brain Tumor Consortium study (PBTC045)
    Meeting Abstract

    Hwang, E.; Kilburn, L.; Mitchell, D.; Lin, T.; Poussaint, T. Y.; Robinson, G.; Gajjar, A.; Lenzen, A.; Dorris, K.; Robison, N.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save